Navigation Links
Agenda set for upcoming global conference on stem cell therapy to be held Jan. 20-21, 2011
Date:1/5/2011

WHAT: The agenda for the Sixth International Conference on Cell Therapy for Cardiovascular Disease (IC3D) has been set and is available at http://celltherapy.crf.org/conference/agenda.html. The conference, which will be held January 20-21, 2011, is a one-and-a-half day comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke. This year's conference will focus on commercialization aspects of the field, highlighting the status of molecular, cell, and tissue products in addition to delivery systems.

WHY: Now in its 10th year of clinical trials, the application of stem cells in the treatment of cardiovascular diseases has seen many notable successes, as well as identified challenges that await the next round of clinical studies. Leaders in the field will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.

Sessions will focus on:

  • Autologous cell products
  • Allogenic cells, hybrid preparations, and specialty products
  • Molecular interventions: Macro and micro agents
  • Delivery methods and imaging
  • Selection of biologics and methodologies in the development of the next generation of clinical trials

WHO: Warren Sherman, MD, Course Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patient's own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.

WHEN: January 20-21, 2011

WHERE: Vivian and Seymour Milstein Family Heart Center
Myrna L. Daniels Auditorium
NewYork-Presbyterian Hospital/Columbia University Medical Center
New York, NY

For more information visit: http://celltherapy.crf.org/

HOW TO REGISTER:

Media may apply for registration by emailing jromero@crf.org.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Bersin & Associates Unveils Agenda for Research Conference, IMPACT 2010: The Business of Talent(R)
2. Scientific community to set research agenda for infection prevention and control for next decade
3. National Democratic Strategist Bob Weiner Discusses Healthcare, Political Aftermath, Obama Agenda in Radio Interview
4. Report proposes new research agenda on pregnancy intentions of HIV-positive women
5. Transformation at top of agenda for CPMRCs annual conference in Jan. 2011
6. Republicans Give Top Award to Betsy McCaughey, Healthcare Patriot, & Rev Up for Upcoming Elections
7. SOKO Fitness & Spa Group to Present at Upcoming Investor Conferences
8. Good Vibrations Announces Upcoming Donation Partner: Clitoraid
9. Marin Cosmetic Surgery Center "The Center of Excellence" Celebrating It's Upcoming Tenth Year Anniversary With Miguel A. Delgado, Jr., M.D.
10. Upcoming Simulcast to Teach Women How to Lose Weight and Naturally Balance Hormones with Polycystic Ovarian Syndrome
11. KidsPlay Unplugged, LLC Launches Website; Announces Production of Upcoming DVD's Encouraging Children to Engage in Free Spirited and Imaginary Play
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: